罗氏总部位于瑞士巴塞尔，是世界领先的以研发为基础的健康事业公司，拥有制药和诊断两大业务。
罗氏在肿瘤、病毒、炎症、代谢和中枢神经系统领域提供真正差异化的药物，是世界最大的生物技术公司；在体外诊断和来自肿瘤组织的病理诊断领域保持世界领先水平；是糖尿病管理领域的开拓者。
罗氏个性化医疗战略旨在为切实提高患者的健康水平、生活质量和生存期提供药品和诊断工具。
2011年，罗氏集团全球共拥有80,000多名员工，并在研发上投入了80多亿瑞士法郎。
罗氏集团销售业绩达425亿瑞士法郎。
美国基因泰克公司是罗氏集团的独资子公司。
罗氏还是日本中外制药株式会社的控股方。
罗氏在以下领域是全球领先者-抗肿瘤领域-病毒学领域-体外诊断领域其他关键治疗领域-自身免疫性疾病-炎症-移植领域-代谢-中枢神经系统疾病罗氏的价值观罗氏的使命1、作为一家领先的健康医疗公司，我们致力于创造，生产和营销高质量的，创新的产品以满足未尽的医疗需求。
2、我们的产品和服务有助于预防、诊断和治疗疾病，从而提升人类健康水平和改善生活质量。
3、我们尽责任，守道德并在个人，社会和环境方面承诺可持续发展。
罗氏制药在中国：作为一家有远见卓识的跨国公司，罗氏早在1926年就来到中国。
1961年在香港设立分支机构，1984年罗氏重返中国大陆市场，并于1994年成立了在中国的第一家合资企业—上海罗氏制药有限公司，总投资额为6235.7万美元，提供肿瘤学、病毒学、移植学等各类关键治疗领域的突破性药物，努力从根本上改善人们的生活质量。
2004年底，罗氏中国药品研发中心在上海张江高科技园区正式落成，再次证明了罗氏对中国的长期承诺。
2007年10月29日，罗氏药品开发中国中心开幕,这是中国乃至亚太地区（不包括日本在内）第一个全功能临床药品开发中心，该中心的建立体现了罗氏在华建成了包含研究、开发、生产、营销等环节在内的完整的医药价值产业链。
2008年11月罗氏厂区扩建项目启动，同时罗氏合作部在上海成立,进一步体现了罗氏致力于在中国发展的长期承诺，更进一步完善了罗氏现有的医药产业价值链。
2009年9月1日起，罗氏制药亚太地区总部落户上海, 罗氏药品开发中国中心也升级为罗氏药品临床研发亚太中心。
罗氏高度重视与中国社会各界的合作，尤其是与中国政府的沟通和合作。
1999年3月，江泽民先生作为国家主席参观了罗氏巴塞尔总部。
2005年，罗氏集团董事会与执行委员会集体访华期间，拜见了国家商务部薄熙来部长和国家食品药品监督管理局邵明立局长。
罗氏集团董事会主席和CEO也有幸成为上海市市长国际企业家咨询会议（IBLAC）成员，为上海投资环境优化、医疗保健体制改革、鼓励自主创新等方面积极献策。
同时，罗氏还非常注重可持续发展，积极参与各种社会公益事业，如赈灾扶贫、捐资赠药、支持教育、关爱患者、热心环保。
作为一家知名的跨国药企，罗氏先后被授予“上海市文明单位”、“高新技术企业”、“外商投资先进企业”、上海市百家“职工最满意的企事业单位”、“中华慈善杰出贡献企业奖”等一系列荣誉。
上海罗氏制药先后被授予2011年，连续第六次获得“上海市文明单位”荣誉称号2011年，获得“2011中国最佳100人力资源典范企业”殊荣2010年，第四届被评为上海市百家“职工最满意的企事业单位”殊荣2010年，荣获“首届长三角医药企业社会责任优秀企业奖”2009年，荣获中华慈善总会颁发的“中华慈善杰出贡献企业奖”2008年，连续第三届被评为上海市的“双爱双评活动十佳先进企业”2007年，被评为“全国双爱双评先进企业”2004年, 入选首届上海市百家“职工最满意企业”“上海市文明单位”、“高新技术企业”、上海市百家“职工最满意的企事业单位”、“外商投资先进企业”等一系列的殊荣罗氏药品临床研发亚太中心：罗氏药品临床研发亚太中心位于上海张江高科技园区，是罗氏在中国乃至亚太地区（不包括日本在内）第一个全功能临床药品开发中心，是罗氏药品开发部在全球的第五个研发地区。
其前身为2007年10月成立的罗氏药品开发中国中心。
罗氏于2007年在中国率先设立全球药品开发中心，成为在华完成且体现药物研究、药品开发、生产制造和市场销售环节等整体价值链布局的跨国制药企业。
此举不仅将加快新药在华的上市时间，使国内广大患者有望更早地受益于创新药物，而且将让更多的中国研究机构、学者、临床医生更早、更主动地参与到全球创新药物的开发过程。
罗氏药品开发中国中心从事药品开发工作，是把经过实验室筛选的分子转变成药物的关键一环，它通过国际多中心临床研究，鉴定药物的安全性和有效性，是驱动药物价值链的引擎。
罗氏药品开发中国中心于2009年9月升级为罗氏药品临床研发亚太中心，负责罗氏在亚太地区的药品开发，令更多中国乃至亚太地区的患者尽早受益。
罗氏研发在中国：罗氏研发（中国）有限公司，位于上海张江高科技园区，是中国第一家由跨国制药企业独资拥有的药物研发中心，我们将通过尝试新的药物研发途径，为国内乃至国际市场提供具有临床差异性的药物。
经过5年的发展，罗氏研发（中国）有限公司从早期药物发现工作起步，建立了从早期研究到早期开发全功能的药物研发业务部门，成为一个在中国拥有大批业内专家和广泛合作伙伴的药物研发组织。
我们正在寻找药物研发行业内的领军人物加入我们，让我们共同创造医疗保健领域的美好明天。
职位职责：在公司政策和程序指引下向指定客户群传达医学信息负责区域内外部客户医学信息沟通和传递，医学教育活动和培训定期开展学术会议，向客户介绍产品在不同适应症上的优点及时收集、提供市场信息并做出适当建议根据区域销售情况合理制定预算，并按计划开展工作与客户建立良好关系，维持公司形象熟练掌握产品知识，定期参加相关产品知识培训及学术会议职位要求：本科及以上学历应届毕业生；医学、药学、临床医学及相关专业优先拥有良好的英语书写及英语口语能力熟练运用Word、Excel、PPT等办公应用软件拥有良好的表达能力、学习能力以及执行能力1896The founding year - first successesF. Hoffmann-La Roche & Co. was founded at a time when industrial revolution was changing the face of Europe. On October 1, 1896, at the age of 28, Fritz Hoffmann-La Roche launched his company as the successor company to Hoffmann, Traub & Co in Basel, Switzerland. The guiding maxim for Fritz Hoffmann-La Roche was to develop and to manufacture novel drugs of uniform strength and quality and to distribute them internationally - a goal still valid today.1897-1914Expansion and internationalisationEarly on Roche starts to expand its business activities. From 1897 to 1910 the production facility in Grenzach, Germany, is greatly expanded and the lion's share of manufacturing is moved there. Fritz Hoffmann-La Roche and his new partner Carl Meerwein do not waste any time in building up a network of European and overseas agents and subsidiaries. Among others Roche opens offices (by 1914) in Milan (Italy), New York (USA), St. Petersburg (Russia), and London (Great Britain).1915-1927The time of crisisThe outbreak of the First World War in August has devastating repercussions for Roche. The German boycott of its products, Basel's isolation from its plant in Grenzach, the loss of the company's Russian market and assets in the Revolution of 1917 and sizeable foreign exchange losses have created a financial crisis. In reaction to this development, Roche is transformed into a limited company. Additionally Roche has to bemoan the death of founding father and visionary Fritz Hoffmann in 1920. A glimmer of hope arises with the classic study of Markus Guggenheim of Biogenic Amines which enhanced the company's standing in the scientific community.1928-1944Vitamin boost overcomes the crisisRoche managed to overcome the cris under the leadership of chairman Emil C. Barell. The company experienced an unexpected upsurge spurred by its vitamin production, which made the return to former prosperity possible. Roche is able to expand once more and starts its strong commitment to the US-American market with first investments in New York and Nutley.1945-1964Streamlining and improving the company's outputVitamin output increases and new production locations strengthens Roche's position as one of the main producers of vitamins. To avoid a strong dependency on vitamins Roche intensifies pharmaceutical research. Between the early 1950s and mid-1960s pharmaceutical research at Roche is extremely diverse, with a portfolio ranging from antidepressants and antimicrobials to agents for cancer chemotherapy. During this time, Roche's researchers come across a compound of the benzodiazepine class which had the desired effect: It sedated without drowsiness.1965-1978DiversificationPropelled by the success of the benzodiazepines, Roche is to branch out into markets spanning the whole spectrum of healthcare. In Switzerland and the United States bioelectronics departments are set up to develop electronicmedical instruments. Rocom and Medicovision are the company's forays into medical publishing. The acquisition of Dr. R. Maag AG, a plant protection company, reflects Roche's growing involvement in the agrochemical sector. The headquarters in Nutley, USA, set up a diagnostics department of its own. This period is also the starting point for Roche's involvement in basic biomedical research reflected by the decision to establish the Roche Institute of Molecular Biology in Nutley, USA, and the Basel Institute for Immunology as well as the Nippon Research Center in Kamakura, Japan. The chemical accident at the plant in Seveso (Italy), a subsidiary of Givaudan is a major setback.1979-1990Reform, Concentration and TransparencyRoche begins to tighten organisational structures and moves towards creating separate business units, which should become more and more autonomous. In addition, corporateactivities are consolidated through selective acquisitions and divestments in various business segments. After a general alignment of the company's structures Roche is left with four core business divisions: pharmaceuticals, vitamins and fine chemicals, diagnostics, and flavours and fragrances.1991-2000International Expansion and Innovative DevelopmentsThrough its firm commitment to research, Roche intends to continue developing innovative advances in drug therapy that will replace more expansive treatments and shorten hospital stay.2000-2006Company Restructure and Focus on BiotechBy sharpening the Group's focus on its core businesses - Pharmaceuticals and Diagnostics -the way of the future development is already paved. With combined expertise in Diagnostics and Pharmaceuticals and strength in biotechnology, Roche is ranked among the world’s leading innovation-driven healthcare companies and is ideally positioned to pursue Personalised Healthcare options.2007-TodayMoving towards Personalised HealthcareThe increased focus on innovation and medical biotechnology has led to important advances in diagnostic techniques and innovative medicines aiming at molecular targets. As a result, many diseases can now be detected earlier and treated more specifically than ever before. The full integration with biotech pioneer Genentech in 2009 follows the acquisitions of other key players in areas spanning from life science research, gene sequencing and tissue diagnostics. They strengthen Roche’s access to innovation and new technologies to drive forward the commitment to more targeted treatments, and ultimately make personalised healthcare a reality.。